IN8bio (INAB, Financial) has released encouraging new preclinical findings from its innovative gamma delta T cell engager platform. Set to be presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting on April 30, 2025, the data highlight the platform's strong and consistent ability to destroy cancer cells, particularly in leukemia models, while minimizing harmful side effects often associated with traditional TCE-based therapies.
Unlike conventional T cell engagers that activate all T cells indiscriminately, often leading to severe side effects, IN8bio’s next-generation platform focuses on selectively activating only gamma delta T cells. This specialized subset of immune cells can naturally identify and eliminate tumor cells without needing prior training to target them. The platform's lead candidates, INB-619 and INB-633, demonstrated the ability to effectively target and destroy cancer cells in preclinical models with minimal cytokine release.
This approach could significantly lower the risk of cytokine release syndrome and neurotoxicity, conditions that can affect 60-75% of patients undergoing treatment with standard CD3 T cell engagers. IN8bio’s advancements promise a more targeted and potentially safer immune therapy option.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for IN8bio Inc (INAB, Financial) is $2.61 with a high estimate of $6.00 and a low estimate of $1.20. The average target implies an upside of 1,280.08% from the current price of $0.19. More detailed estimate data can be found on the IN8bio Inc (INAB) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, IN8bio Inc's (INAB, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
